- active not recruitingPHASE1, PHASE2
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
This study is testing a new medicine called epcoritamab for people with certain types of B-cell lymphoma that have come back or not responded to previous treatments. It aims to find the right dose, understand side effects, and see how well it works.
United States · Australia · Canada - ongoing, recruitingTherapeutic exploratory (Phase II)
Axicabtagene Ciloleucel CAR T-Cells in Patients with relapsed or refractory primary mediastinal B-Cell Lymphoma
This study is looking at a special type of cell therapy, called CAR T-cell therapy (Yescarta), for people with a type of lymphoma called primary mediastinal B-cell lymphoma (PMBCL). It aims to see how well this treatment can get rid of the cancer after three months, especially if other treatments haven't worked.
Germany